NewsRoom Articles - PsychedelicNewsWire (PNW)

MondayApr 19, 2021 12:40 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces LOI Aimed at U.S. Expansion

Pure Extracts plans affiliate partnership to install cannabis and hemp extraction system in existing Michigan facility Company CEO notes excitement about launching into first US initiative with experienced and entrenched partners Agreement outlines planned renovation of existing 2,600-square-foot facility located in central Michigan Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, has inked a letter of intent (“LOI”) to form a joint venture that paves the way for the company’s entrance into the United States. Based on the LOI, PULL will partner with the affiliate of a publicly traded multi-state…

MondayApr 19, 2021 11:31 am

Could Blockchain Tech Be a Boon for Psychedelics?

In the first few months of 2018, the Multidisciplinary Association for Psychedelic Studies was struggling to raise the finances it needed to conclude phase 3 of its clinical trials, which would allow the FDA to approve its MDMA-assisted therapy. Surprisingly, the funds were availed to the nonprofit organization through cryptocurrency. An anonymous individual, using the name Pine, created a philanthropic project that has made donations to 60 charities in the form of Bitcoin, known as the Pineapple Fund. The anonymous donor donated $5 million dollars’ worth of Bitcoin to MAPS, which enabled the organization to continue with its invaluable research…

FridayApr 16, 2021 12:30 pm

Researchers to Study Effects of Nature-Themed Film on Psilocybin-Assisted Therapy

With psychedelics going mainstream, it should come as no surprise that researchers are planning to conduct a trial evaluating the treatment of alcohol use disorder using psilocybin, which is commonly known as a magic mushroom. Director of the Pacific Neuroscience Institute Daniel Kelly, who is also a neurosurgeon, will be carrying out the trial using a new approach, which will also employ the use of a nature-themed video. The filmmaker who created the video, Louie Schwartzberg, asserted that the film was not only historic but also truly groundbreaking work. Prior research has shown that video can enhance a psychedelic experience…

FridayApr 16, 2021 12:15 pm

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profile Mescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort that produced a wave of cannabis product legalization Mescaline has historically defied predictable outcomes by researchers, but advocates cite it as a means of successfully treating some mental health and substance abuse disorders A number of psychedelics production stocks saw huge gains during the past…

ThursdayApr 15, 2021 12:00 pm

California Senate Committee Approves Psychedelic Decriminalization Measure

Earlier this month, a measure to decriminalize psychedelics in the state of California was advanced to the Senate Public Safety Committee. The committee also passed a separate bill that would enable communities in the state to temporarily open safe consumption sites for illegal drugs. The legislation, sponsored by Sen. Scott Wiener, was approved by the Senate Public Safety Committee. If the bill is enacted into law, it would remove criminal penalties imposed on the distribution or possession of an extensive range of psychedelics, including MDMA, LSD, ibogaine, DMT and psilocybin mushrooms, for individuals aged 21 and above. The initiative would…

WednesdayApr 14, 2021 12:00 pm

Women in the Psychedelic Field and the Barriers That Held Them Back

Women have contributed greatly to the psychedelics industry, accomplishing incredible research and work in the field, despite being maligned in serious ways for just being involved. Given that International Women’s Month has just ended, the timing seems ideal to shine a spotlight on women pioneers of psychedelics, along with a focus on what exactly held them back. Women have had to jump through hurdles that did not exist for their male counterparts as well as bypass barriers in various industries and fields, including the field of psychedelic research. Knowledge of history or sometimes just personal experience has shown that the…

TuesdayApr 13, 2021 2:15 pm

Another City in Massachusetts Approves Measure to Decriminalize Psychedelics

A third city in Massachusetts, Northampton, has passed an initiative to make the distribution, use and possession of various psychedelics, such as ayahuasca and psilocybin, one of the lowest priorities of law enforcement in the area. Prior to this, the cities of Cambridge and Somerville had also approved measures to effectively decriminalize psychedelics. The Northampton City Council approved the measure, which also stipulates that no police or government funds should be utilized in enforcing laws that criminalize individuals for the possession or use of entheogenic fungi and plants. The city council voted on the resolution this past week, with a…

MondayApr 12, 2021 3:00 pm

New UCSF Research Program to Focus on Psychedelics Research and Treatments’ Advancement

The formation of the University of California Neuroscape Psychedelics Division will help advance psychedelic research on brain health through $6.4 million in private financing. The new division at UCSF will employ a translational research approach that will integrate psychedelic treatment with groundbreaking neuroscience technology. The first project to be undertaken will be a MAPS phase 3 trial for the evaluation of MDMA, commonly known as ecstasy, as a new PTSD treatment. Neuroscape executive director Adam Gazzaley stated that the financiers of the center are helping facilitate a great leap forward in producing evidence of the clinical safety and effectiveness of…

MondayApr 12, 2021 2:10 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations

PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada Near term milestones include Canada-based human clinical trials Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently signed a Letter of Intent with the Psyence Group to develop premium extraction techniques for the production of…

MondayApr 12, 2021 1:01 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April XPhyto has just completed a rebranding effort that includes…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050